Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Piper Sandler
Research analysts at Piper Sandler began coverage on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Get Free Report) in a note issued to investors on Friday, MarketBeat Ratings reports. The brokerage set a “neutral” rating and a $46.00 price target on the stock. Piper Sandler’s target price points to a potential upside of 17.20% from the […]
More Stories
Insider Selling: Peyto Exploration & Development Corp. (TSE:PEY) Director Sells 1,070 Shares of Stock
Peyto Exploration & Development Corp. (TSE:PEY – Get Free Report) Director Stephen Jonathan Chetner sold 1,070 shares of the stock...
Insider Selling: Peyto Exploration & Development Corp. (TSE:PEY) Director Sells 1,070 Shares of Stock
Peyto Exploration & Development Corp. (TSE:PEY – Get Free Report) Director Stephen Jonathan Chetner sold 1,070 shares of the stock...
Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 9,868 Shares of Stock
Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 9,868 shares of the company’s stock...
Insider Selling: Hims & Hers Health, Inc. (NYSE:HIMS) CFO Sells 9,868 Shares of Stock
Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 9,868 shares of the company’s stock...
Marsh & McLennan Companies, Inc. (NYSE:MMC) Receives $215.81 Consensus Target Price from Analysts
Shares of Marsh & McLennan Companies, Inc. (NYSE:MMC – Get Free Report) have earned an average recommendation of “Hold” from...
Marsh & McLennan Companies, Inc. (NYSE:MMC) Receives $215.81 Consensus Target Price from Analysts
Shares of Marsh & McLennan Companies, Inc. (NYSE:MMC – Get Free Report) have earned an average recommendation of “Hold” from...